Abstract
As prostate cancer is the second leading cause of death after lung cancer, several diagnostic strategies have been introduced in recent years. Among these prostate-specific antigens, it is widely recognized that this is the simplest and most common clinical endpoint - genetic instability is part of the oncogenic process. Gene mutations involved in DNA repair mechanisms may promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, abnormalities in DNA repair are primarily due to somatic or constitutional mutations in the BRCA1/2 genes. Treatment options for prostate cancer are currently widely discussed in the media and by urological associations. Focal therapy is expected to have the same oncological efficacy as whole gland therapy with fewer side effects. Accurate diagnosis with multipara metric magnetic resonance imaging (MRI). In this review we examine the various studies described present the molecular targets for personalized prostate cancer therapy.
Publisher
Mediterranean BioMedical Journals
Reference21 articles.
1. S. E. Jackson and J. D. Chester, “Personalised cancer medicine,” Int J Cancer, vol. 137, no. 2, pp. 262–266, Jul. 2015, doi: 10.1002/ijc.28940.
2. S. Zhou, “Clinical pharmacogenomics of thiopurine S-methyltransferase,” Curr Clin Pharmacol, vol. 1, no. 1, pp. 119–128, Jan. 2006, doi: 10.2174/157488406784111627.
3. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA Cancer J Clin, vol. 69, no. 1, pp. 7–34, 2019, doi: 10.3322/caac.21551.
4. T. Grozescu and F. Popa, “Prostate cancer between prognosis and adequate/proper therapy,” J Med Life, vol. 10, no. 1, pp. 5–12, Mar. 2017.
5. L. Remontet et al., “Cancer incidence and mortality in France over the period 1978-2000,” Rev Epidemiol Sante Publique, vol. 51, no. 1 Pt 1, pp. 3–30, Feb. 2003.